13-cis-retinoic acid (isotretinoin) unmasking of clinical polycystic ovary syndrome

Endocrine Practice

Volumn 13, Issue 7, 2007, Pages 776-779

  Pham, Tan ^a   Hal Scofield, R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; ISOTRETINOIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTOSTERONE;

ACNE VULGARIS; ADULT; AMENORRHEA; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE;

ACNE VULGARIS; ADULT; AMENORRHEA; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FOLLICLE STIMULATING HORMONE; HIRSUTISM; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; ISOTRETINOIN; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE;

EID: 38949102094     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.7.776     Document Type: Article

References (15)

1. De Marchi MA, Maranhao RC, Brandizzi LI, Souza DR. Effects of isotretinoin on the metabolism of triglyceride-rich lipoproteins and on the lipid profile in patients with acne. Arch Dermatol Res. 2006;297:403-408.
2. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med. 1985;313:981-985.
3. Baxter KF, Ling TC, Barth JH, Cunliffe WJ. Retrospective survey of serum lipids in patients receiving more than three courses of isotretinoin. J Dermatolog Treat. 2003;14:216-218.
4. Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P. Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diab Metabol Res Rev. 2001;17:391-395.
5. Cortese C, Corona R. Taking advantage of a side effect of isotretinoin. Arch Dermatol. 2003;139:376-377.
6. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001;52:401-419.
7. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006;29:270-280.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
9. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
10. Skrha J, Haas T, Sindelka G, et al. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab. 2004;89:135-141.
11. Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med. 2002;136:582-589.
12. Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans. Metabol Clin Exp. 2004;53:4-10.
13. Sedova L, Seda O, Krenova D, Kren V, Kazdova L. Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. Int J Obes Relat Metab Disord. 2004;28:719-725.
14. Vu-Dac N, Gervois P, Torra IP, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor: contribution to the hypertriglyceridemic action of retinoids. J Clin Invest. 1998;102:625-632.
15. Gustafson S, Vahlquist C, Sjöblom L, Eklund A, Vahlquist A. Metabolism of very low density lipoproteins in rats with isotretinoin (13-cis retinoic acid)-induced hyperlipidemia. J Lipid Res. 1990;31:183-190.